Please find enclosed disclosure

25th August, 2026 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai 400 001 Bandra Kurla Complex Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBERG Societe Anonyme 35A Boulevard Joseph II L-1840 Luxembourg Sub: USFDA inspection at Company’s manufacturing facility in Pithampur, India Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our earlier intimations on the captioned subject dated 18th February 2023, 5th August 2023, and 18th November 2023, we hereby notify that the United States Food and Drug Administration (‘USFDA’) has conducted a follow-up current Good Manufacturing Practices (cGMP) inspection at the Company’s manufacturing facility at Pithampur, India from 17th August 2026 to 25th August 2026. On conclusion of the inspection, the Company received seven (7) inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time. Kindly take the above information on record. Thanking you, Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Chirag Hotchandani Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380